NCT06648785View on ClinicalTrials.gov

Modified Capecitabine and Oxaliplatin (mCAPOX) for Patients with GI Malignancies

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
GI Cancers
Interventions
DRUG

oxaliplatin

85 mg/m2 oxaliplatin

DRUG

Fluoropyrimidine

oral fluoropyrimidine 1000mg/m2

Trial Locations (2)

05401

University of Vermont Medical Center, Burlington

University of Vermont, Burlington

All Listed Sponsors
lead

University of Vermont Medical Center

OTHER